Knight
Manufacturing · Canada · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
100 Boul Alexis-Nihon Bureau 600, Saint-...Phone Number
(514) 484-4483Website
www.knighttx.comRevenue
$236.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Knight
Knight Therapeutics Inc., headquartered in Montreal, is a specialty pharmaceutical company focused on acquiring, licensing, marketing, and commercializing innovative prescription medicines across Canada and Latin America. With operations in multiple countries, it delivers a diverse portfolio of pharmaceuticals while building long-term partnerships with leading global pharmaceutical companies to advance healthcare and patient access throughout the region.Explore more
Knight Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Knight your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Knight has new funding data
Check if Knight has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Knight
Click to see if Knight had a recent Job posting/layoffs
Knight, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Knight is spiking on competitors!
Earning: See what the market has to say on Knight recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Knight launches new products
Recommended Actions
Find VP level buyers at Knight
Find 3 more new buyers
Company Profile Activity
Activity Insights
Knight is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Knight is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Knight.
Knight Tech Stack
A closer look at the technologies used by Knight
See more technologies
Most Recent Scoops
Project
Knight has announced plans to launch TAVALISSE in Brazil following regulatory approval received earlier this quarter, as well as WYNZORA in Canada and certain branded generics in Latin America in H2 2026.
Pain Point
Knight has received a Notice of Non-Compliance from Health Canada regarding its new drug submission for CREXONT, and will be working with its partner to respond, noting that CREXONT is already approved in the US and received a positive CHMP recommendation in Europe with approval expected in September.
Compliance
Pain Point
Knight has announced that LENVIMA in Colombia is subject to a regulated price review that is expected to result in a material price decrease, and that a branded generic and a generic competitor have been approved and are expected to launch by end of 2024 or early 2025, with both the pricing impact and generic competition already incorporated into the company's guidance.
Pharmaceuticals
Earnings
Knight has reported a net loss of CAD 12 million for Q2 2026, driven by mark-to-market revaluations of its strategic fund and equity investments, while its financial assets are valued at CAD 81 million and its funds have generated CAD 51 million since 2020.
Earnings, Business Finance, Finance, Financial Operations
Pain Point
Contracts
Knight News & Media
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adultKnight Therapeutics Announces Launch of WYNZORA® in Canada
MONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of WYNZORA®, a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada. WYNZORA® is indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12 and older.1Knight Therapeutics Inc. (GUD:CA) Q2 2026 Earnings Call Transcript
Knight Therapeutics Inc. (GUD:CA) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsSamira Sakhia - President, CEO & DirectorArvind...Knight Therapeutics Reports Second Quarter 2026 Results
Increased 2026 guidance and expect revenues of $540 million to $560 million Achieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million
Read more news
Top Manufacturing Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Knight
Sign Up For FreeTo access detailed company insights
Knight Therapeutics Inc., headquartered in Montreal, is a specialty pharmaceutical company focused on acquiring, licensing, marketing, and commercializing innovative prescription medicines across Canada and Latin America. With operations in multiple countries, it delivers a diverse portfolio of pharmaceuticals while building long-term partnerships... Read More
